ImaRx Therapeutics Reports Second Quarter Ended 2009 Financial Results

REDMOND, Wash., Aug. 11, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a development-stage biopharmaceutical company, whose research and development efforts have focused on the development of therapies for stroke and other vascular disorders leveraging its proprietary microsphere and ultrasound technology, today reported financial results for the second quarter ended June 30, 2009.

Back to news